KVISTGAARD, Denmark - March 4, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will host an investor and analyst conference call on Thursday, March 5, 2015 at 2:00 pm CET (8:00 am EST) to discuss the agreement with Bristol-Myers Squibb for PROSTVAC that the Company has announced today.
Dial-in numbers for the conference call are:
Denmark: +45 32 72 80 18
UK: +44 (0) 844 571 8957
USA: +1 866 682 8490
A live and archived webcast of the call and relevant slides will be available at http://bit.ly/1wUI1cr
Contacts
U.S.: Seth Lewis, Vice President, Investor Relations. Phone: + 1 978-341-5271
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43
About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. For more information, please visit www.bavarian-nordic.com or follow us on Twitter at http://twitter.com/bavariannordic.